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1. Introduction  
Type 1 diabetes mellitus is by far the most common metabolic and endocrinal disease in 
children (Peters & Schriger, 1997). The major dietary component responsible for fluctuations 
in blood glucose levels is carbohydrate. The amount, source (Jenkins et al., 1981; Gannon et 
al., 1989) and type (Brand et al., 1985) of carbohydrate appear to have profound influence on 
postprandial glucose levels. The chronic hyperglycemia of diabetes is associated with long-
term damage, dysfunction and failure of various organs especially the eyes, kidneys, nerves, 
heart and blood vessels (American Diabetes Association, 2001).  
The glycemic effect of any foodstuff is defined as its effect on blood glucose level 
postprandially. Both the glycemic index (GI) and the peak incremental index (PII) are used 
to assess the glycemic effect of different food stuffs (Jenkins et al., 1981). Jennie et al (2003) 
who studied the use of low glycemic index diets in the management of diabetes found that 
diets with low glycemic indices (GI), compared with conventional or high-GI diets, 
improved overall glycemic control in individuals with diabetes, as assessed by glycemic 
index, peak incremental index, reduced HbA1c and fructosamine. They concluded that 
using low-GI foods in place of conventional or high-GI foods has a clinically useful effect on 
postprandial hyperglycemia similar to that offered by pharmacological agents that target 
postprandial hyperglycemia. Similarly, the American Diabetes Association (2002) stated that 
the use of low-GI foods may reduce postprandial hyperglycemia. 
Honey is the substance made when the nectar and sweet deposits from plants are gathered, 
modified and stored in the honeycomb by honey bees. It is composed primarily of the 
sugars glucose and fructose; its third greatest component is water. Honey also contains 
numerous other types of sugars, as well as acids, proteins and minerals (White et al., 1962; 
White, 1980; White, 1975). The water content of honey ranges between 15 to 20% (average 
17.2%). Glucose and fructose, the major constituents of honey, account for about 85% of the 
honey solids. Besides, about 25 different sugars have been detected. The principal 
oligosaccharides in blossom honeys are disaccharides: sucrose, maltose, turanose, erlose. 
Trace amounts of tetra and pentasaccharides have also been isolated (Bogdanov, 2010). The 
protein and amino acid content of honey varies from 0.05 to 0.3 %. The honey proteins are 
mainly enzymes (White, 1975). Honey also contains varying amounts of mineral substances 
ranging from 0.02 to 1.03 g/100 g (White, 1975). Among honey benefits are its anti-
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inflammatory (Al Waili & Boni, 2003), anti- oxidant (Frankel et al., 1998; Gheldof & 
Engeseth, 2002; Gross et al., 2004) and anti-microbial effects (Molan, 1992; Steinberg et al., 
1996; Molan, 1997; Theunissen et al., 2001). Further-more, several studies have shown that 
honey produced an attenuated postprandial glycemic response when compared with 
sucrose in both patients with diabetes and normal subjects (Ionescu-Tirgoviste et al., 1983; 
Shambaugh et al., 1990; Samanta et al., 1985; Al Waili, 2004; Agrawal et al., 2007). 
C-peptide is considered to be a good marker of insulin secretion and has no biologic activity 
of its own (Ido et al., 1997). Measurement of C-peptide, however, provides a fully validated 
means of quantifying endogenous insulin secretion. C-peptide is co-secreted with insulin by 
the pancreatic cells as a by-product of the enzymatic cleavage of proinsulin to insulin. 
Consequently, serum C-peptide level can be used as a true indicator of any change in the 
insulin level, which is the main determinant of plasma glucose level. 
Several studies were performed in healthy and in type 2 diabetic patients to evaluate the 
effects of honey on the insulin and C-peptide levels, and the results were controversial 
(Bornet et al., 1985; Elliott et al., 2002; Watford, 2002; Al-Waili, 2003). 
2. Aim of the study 
The aim of this work was to compare the effects of honey, sucrose and glucose on plasma 
glucose and C-peptide levels in children and adolescents with type 1 diabetes mellitus. 
3. Subjects and methods 
3.1 Subjects 
Twenty patients with type 1 diabetes mellitus, aged 3–18 (mean 10.95 years) and ten healthy 
non-diabetic children and adolescents, aged 1–17 (mean 8.5 years) were studied. All subjects 
were within 68–118% and 77–125% of their ideal body weight and height, respectively. The 
mean BMI of patients and controls were 22.60 and 23.15, respectively. All patients with 
diabetes had a mean glycosylated hemoglobin of 9.9% (range = 7–15%). The sex ratio in 
patients and controls was 1:1. The patients were recruited from the regular attendants of the 
children clinic of the National Institute of Diabetes in Cairo, Egypt. The study was approved 
by the local ethical committee, and an informed written consent was obtained from at least 
one parent of each subject before the study. All patients were receiving three insulin 
injections per day, each consisting of a mixture of a medium-acting insulin (isophane NPH) 
and a short-acting soluble insulin (human Actrapid). 
3.2 Methods 
All patients were primarily diagnosed with type 1 insulin-dependent diabetes mellitus by 
measuring the serum level of C-peptide on presentation [the patient was considered 
suffering from insulin-dependent diabetes mellitus type 1 if the C-peptide level was below 
0.4 ng/dl (Connors, 2000)]. All subjects were subjected to the following: 
1.  Anthropometric measures including weight in kg and height in cm which were plotted 
against percentiles for age and sex. 
2.  Oral sugar tolerance tests using glucose, sucrose and honey in three separate sittings: 
After an overnight fast (8 h) and omission of the morning insulin dose, a calculated 
amount of each sugar (amount = weight of subject in kg X 1.75 with a maximum of 75 g) 
(William & Ruchi, 2005) was diluted in 200 ml water and then ingested over 5 min in a 
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random order, on separate mornings 1 week apart. The honey dose for each patient was 
calculated based on the fact that each 100 gm of the honey used in this study contained 
77.3 gm sugars. So if a patient weighs for example 20 kg, he/she should receive 20 x 
1.75 = 35 gm sugar which will be present in (35 x 100) ÷ 77.3 = 45.3 gm honey. Venous 
blood was sampled just before ingestion and then every 30 min postprandial for 2 h 
thereafter. Samples were left to clot, centrifuged and glucose assay was performed 
chemically on the Synchron CX5 autoanalyzer (Beckman instruments Inc.)1.  
3. Measurement of fasting and postprandial serum C- peptide level: Venous blood 
samples were withdrawn from each subject at 0 (fasting) and 2 h postprandial after 
ingestion of each individual sugar. The samples were then centrifuged and serum was 
stored in aliquots at – 20°C. At the end of the study, samples were calibrated for C-
peptide using the biosource c-pep-easia2, which is a solid phase enzyme amplified 
sensitivity immunoassay performed on a microtiter plate. A fixed amount of C-peptide 
labeled with horseradish peroxidase (HRP) competes with unlabeled C-peptide present 
in the calibrators controls and samples for a limited number of binding sites on a 
specific antibody. After 2 h incubation at room temperature, the microtiter plates were 
washed to stop the competition reaction. The chromogenic solution (TMB-H2O2) was 
added and incubated for 30 min. The reaction was stopped with the addition of stop 
solution, and the microtiter plate was then read at the appropriate wave length. The 
amount of substrate turnover was determined colorimetrically by measuring the 
absorbance which was inversely proportionate to the C-peptide concentration. A 
calibration curve was plotted and C-peptide concentration in samples was determined 
by interpolation from the calibration curve.  
4. Calculation of glycemic and peak incremental indices (see example figure 3.1):  
   Area under glycemic curve of test foodGlycemic index ً◌ of the food Jenkins, 1987  =
Area under glycemic curve of glucose
  
 Area under curve (AUC) refers to the area included between the baseline and 
incremental blood glucose points when connected by straight lines. The area under each 
incremental glucose curve is calculated using the trapezoid rule (note: only areas above 
the baseline are used).  
 Peak incremental index (PII) (Samanta et al., 1985) is defined as the ratio of the maximal 
increment of plasma glucose produced by sugar to that produced by glucose 
 
Maximal increment produced by the sugar tested
Peak incremental index  
Maximal increment produced by glucose
   
Maximal increment is the difference between the peak point and the fasting point. 
3.3 Statistical analysis 
Standard computer program SPSS for Windows, release 13.0 (SPSS Inc., USA) was used for 
data entry and analysis. All numeric variables were expressed as mean ± standard deviation 
(SD). Comparison of different variables in various groups was done using student t-test and 
Mann–Whitney test for normal and non-parametric variables, respectively. Wilcoxon signed 
                                                 
1 Beckman: 2005, kraemerBLW, Brew, CA 92621, USA. 
2 Biosource Europe S.A—Rue de lindustrie, 8-B-1400-Nivelles-Belgium.  
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rank tests were used to compare multiple readings of the same variables. Chi-square (χ2) 
test was used to compare frequency of qualitative variables among the different groups 
(Daniel, 1995). 
 
 
Fig. 3.1 Oral glucose tolerance curve of one of our patients 
For calculation of the area under honey curve (AUC) =A1+A2+A3+A4 
A1 is a triangle = 1/2 base x height = 1/2(X2 - X1) x (Y1 - X2) = ½(30) x (144 – 89) = 15 x 55 = 
825 
A2 is a trapezoid = 1/2 sum of the parallel sides (heights) x base 
= 1/2[(Y1 - X2) + (Y2- X3)] ×(X4- X5) = 1/2[(144 – 89) + (225 – 89)] x 30 = 1/2(55 + 136) x 30 = 
1/2(191) x 30 = 95.5 x 30 = 2865 
A3 is a trapezoid = 1/2 sum of the parallel sides (heights) x base 
= 1/2[(Y2 – X3) + (Y3- X4)] ×(X4- X3) = 1/2[(225 – 89) + (245 – 89)] x 30 = 1/2(136 + 156) x 30 
= 1/2(292) x 30 = 146 x 30 = 4380 
A4 is a trapezoid = 1/2 sum of the parallel sides (heights) x base 
= 1/2[(Y3 – X4) + (Y4- X5)] ×(X3- X2) = 1/2[(245 – 89) + (128 – 89)] x 30 = 1/2(156 + 39) x 30 = 
1/2(195) x 30 = 97.5 x 30 = 2925 
AUC = A1 + A2 +A3 + A4 = 825 + 2865 + 4380 + 2925 = 10995 
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4. Results 
No significant difference was found between patients (diabetics) and controls (non-
diabetics) as regards the age and anthropometric measures (table 4.1). The mean age of 
subjects in the diabetic and non- diabetic groups was 11.3 and 8.5 years, respectively, with 
no statistically significant difference between groups (P > 0.05). The mean weight %, 
height % and body mass index did not also differ significantly between diabetics and non- 
diabetics (93.6%, 99.2%, 22.6 versus 94%, 98.2%, 23.1, respectively; P > 0.05). The mean 
plasma glucose level at 0 (fasting) and 30 min postprandial (i.e. 30 min after intake of 
glucose, sucrose or honey) did not differ significantly between subjects in both groups 
(diabetics and non-diabetics) (Tables 4.2 - 4.5) (P > 0.05). In non-diabetics (control), as 
shown in tables 4.2 and 4.3, the mean plasma glucose level 60, 90 and 120 min after intake 
of honey became significantly lower than after either glucose or sucrose (P< 0.05). 
Similarly, as shown in tables 4.4 and 4.5, there was a statistically significant decrease of 
plasma glucose in diabetics at 60, 90 and 120 min after honey intake, when compared with 
either glucose or sucrose (P< 0.05). The glycemic index (GI) and the peak incremental 
index (PII) of either sucrose or honey did not differ significantly between patients and 
controls (P > 0.05). On the other hand, both the GI and PII of honey were significantly 
lower when compared with sucrose in patients and controls.  In non-diabetics, the 
glycemic index (GI) of honey was 0.69 compared to 1.32 for sucrose, with statistically 
significant difference (P< 0.05). In diabetics, the GI of honey was also significantly lower 
than that of sucrose (o.61 versus 1.19, respectively; P< 0.001) (table 4.6; figure 4.1).  The PII 
of honey in non-diabetics was 0.61, compared to 1.25 for sucrose (P< 0.05). In diabetics, 
the PII of honey was also significantly lower than that of sucrose (0.60 versus 1.10, 
respectively; P< 0.001) (table 4.7; figure 4.2).  
The mean (±SD) fasting C-peptide of patients and controls were 0.15 (±0.13) and 1.91 (±0.77) 
ng/ml, respectively (P< 0.001). All diabetic patients had a basal C-peptide level less than 0.7 
ng/ml. In diabetics, although honey intake resulted in increase in the mean level of C-
peptide, yet this increase was not statistically significant when compared with either glucose 
or sucrose (P> 0.05) (Table 4.8; figure 4.3). On the other hand, in non-diabetics, honey 
produced a statistically significant higher C-peptide level, when compared with either 
glucose or sucrose (P< 0.05) (Table 4.8; figure 4.4).  
 
 
Variable Diabetics Non-diabetics P 
Age (yr) 11.30 ± 4.80 8.50 ± 5.38 >0.05 
Weight % 93.60 ± 13.82 94.00 ± 14.28 >0.05 
Height % 99.20 ± 13.01 98.20 ± 11.14 >0.05 
BMI 22.59 ± 5.50 23.14 ± 2.90 >0.05 
 
P > 0.05 is non significant  
BMI: Body Mass Index 
 
Table 4.1 Age and anthropometric measures in diabetics and non-diabetic controls  
(mean ± SD) 
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Time (min) Glucose Honey P 
0 75.20 ± 17.45 72.30 ± 9.09 > 0.05 
30 86.00 ± 19.88 83.30 ± 9.52 > 0.05 
60 102.90 ± 24.47 88.80 ± 10.04 < 0.05 
90 103.60 ± 21.24 88.50 ± 8.64 < 0.05 
120 91.10 ± 20.74 81.00 ± 8.30 < 0.05 
Table 4.2 Mean plasma glucose (±SD) (mg/dl) in non-diabetics (control) following 
equivalent amount of glucose or honey (P < 0.05 is significant) 
 
Time (min) Sucrose Honey P 
0 68.50 ± 12.59 72.30 ± 9.09 > 0.05 
30 83.80 ± 13.56 83.30 ± 9.52 > 0.05 
60 101.60 ± 11.45 88.80 ± 10.04 < 0.05 
90 105.40 ± 18.03 88.50 ± 8.64 < 0.05 
120 93.60 ± 17.25 81.00 ± 8.30 < 0.05 
Table 4.3 Mean plasma glucose (±SD) (mg/dl) in non-diabetics (control) following 
equivalent amount of sucrose or honey (P < 0.05 is significant) 
 
Time (min) Glucose Honey P 
0 206.05 ± 95.79 208.10 ± 92.76 > 0.05 
30 257.55 ± 92.79 247.75 ± 99.44 > 0.05 
60 339.80 ± 96.86 285.50 ± 86.29 < 0.05 
90 328.05 ± 99.75 272.25 ± 85.33 < 0.05 
120 297.90 ± 106.86 236.75 ± 76.80 < 0.05 
Table 4.4 Mean plasma glucose (±SD) (mg/dl) in diabetics following equivalent amount of 
glucose or honey (P < 0.05 is significant) 
 
Time (min) Sucrose Honey P 
0 198.30 ± 77.762 208.10 ± 92.76 > 0.05 
30 268.25 ± 78.78 247.75 ± 99.44 > 0.05 
60 320.35 ± 67.17 285.50 ± 86.29 < 0.05 
90 323.65 ± 71.27 272.25 ± 85.33 < 0.05 
120 310.15 ± 92.63 236.75 ± 76.80 < 0.05 
Table 4.5 Mean plasma glucose (±SD) (mg/dl) in diabetics following equivalent amount of 
sucrose or honey (P < 0.05 is significant) 
 
 
Sucrose Honey  
P GI GI 
Non- diabetics 1.32 (0.85–1.92) 0.69 (0.43–1.43) < 0.05 
Diabetics 1.19 (0.31–3.08) 0.61 (0.15–1.92) < 0.001 
Table 4.6 Glycemic index (GI) mean (range) of sucrose and honey (glycemic index of glucose 
= 1) (P < 0.05 is significant; P < 0.001 is highly significant) 
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Fig. 4.1 Glycemic index of sucrose and honey 
 
 
Sucrose Honey 
P 
PII PII 
Non- diabetics 1.25 (0.50–1.82) 0.61 (0.30–1.10) < 0.05 
Diabetics 1.10 (0.65–2.98) 0.60 (0.20–1.60) < 0.001 
Table 4.7 Peak incremental index (PII) mean (range) of sucrose and honey (peak incremental 
index of glucose = 1) (P < 0.05 is significant; P < 0.001 is highly significant) 
 
 
Fig. 4.2 Peak incremental index of sucrose and honey 
P < 0.05 
P < 0.05
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Group 
C-peptide (ng/ml) 
P 
After glucose After sucrose After honey 
Non-diabetics 3.96 ± 0.84 3.99 ± 1.10 5.50 ± 1.15 P < 0.05 
Diabetics 0.29 ± 0.53 0.32 ± 0.53 0.47 ± 1.09 P > 0.05 
Table 4.8 Mean C-peptide (±SD) (ng/ml) following equivalent amount of glucose, sucrose or 
honey in non-diabetics and diabetics (P < 0.05 is significant) 
 
 
Fig. 4.3 C-peptide following equivalent amount of glucose, sucrose or honey in diabetics 
 
 
Fig. 4.4 C-peptide following equivalent amount of glucose, sucrose or honey in non-diabetics 
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5. Discussion  
As shown in many studies, sustained hyperglycemia is a risk factor for both micro vascular 
and macro vascular (as cardiovascular) complications in type 2 diabetes mellitus (Laakso & 
Lehto, 1997; Bretzel et al., 1998 as cited from Oizumi et al., 2007), while postprandial 
hyperglycemia has also been considered a risk factor for cardiovascular complications 
(Tominaga et al., 1999; Risso et al., 2001; Chiasson et al., 2002; Hanefeld et al., 2004; 
Nakagami et al., 2004 as cited from Oizumi et al., 2007). Many experimental and 
epidemiological studies have shown that increased postprandial plasma glucose levels may 
have equally or even more harmful effects than fasting hyperglycemia (Tominaga et al., 
1999; Risso et al., 2001; Nakagami et al., 2004 as cited from Oizumi et al., 2007), and the 
reduction of postprandial plasma glucose levels delays the development of cardiovascular 
complications (Chiasson et al., 2002; Hanefeld et al., 2004 as cited from Oizumi et al., 2007).  
Jenkins (1987) defined the glycemic index as the ratio between the blood glucose areas 
produced after ingestion of a studied sugar compared to the blood glucose area produced 
after glucose ingestion itself. He stated that the glycemic response to food affects the insulin 
response which in turn is also potentiated by other non-glucose dependent factors in this 
food (Ostman et al., 2001). On the other hand, FAO/WHO (1998) defined the glycemic index 
as the incremental blood glucose area (0–2 h) following ingestion of 50 g of available 
carbohydrates (no fibers or resistant starch included), expressed as a percentage of the corre-
sponding area following an equivalent amount of carbohydrate from a standard reference 
product. Samnata et al (1985) defined the peak incremental index of a certain sugar as the 
ratio between the maximal increments of the glucose level after ingestion of the sugar 
compared to the maximal increment produced after ingestion of glucose. He also mentioned 
that both the glycemic and the peak incremental indices are closely related, highly 
dependent and positively correlated to the plasma glucose produced after ingestion of any 
given sugar. Therefore, any change in the plasma glucose level after ingestion of a certain 
sugar will markedly affect both the glycemic index and the peak incremental index. Hence, 
the glycemic and the peak incremental indices measure how fast and how much a food 
raises blood glucose levels. Foods with higher index values raise blood sugar more rapidly 
than foods with lower index values do in case of the glycemic index and much more in case 
of peak incremental index.  
In our study, no statistically significant differences were found between diabetic patients 
and non-diabetic controls regarding the glycemic and the peak incremental indices of the 
studied sugars. Similarly, Samnata et al (1985), who studied the glycemic effect of glucose, 
sucrose and honey in 12 normal volunteers, eight patients with insulin-dependent diabetes 
mellitus (IDDM) and six patients with non-insulin-dependent diabetes mellitus (NIDDM), 
found no significant differences between the normal volunteers and diabetic patients 
regarding the glycemic and peak incremental indices of both sugars. Since the glycemic 
index (GI) is the ratio between the area under curve (AUC) of the studied sugar and the 
AUC of glucose, and the peak incremental index (PII) is the ratio between the maximal 
blood glucose increment of the studied sugar and that of glucose; it may be expected that 
both GI and PII will be the same in both diabetics and non-diabetics. Our study showed that 
honey has statistically significant lower glycemic and peak incremental indices than sucrose 
and glucose in both patients and controls (< 1 with honey, 1 with glucose being the reference 
sugar and >1 with sucrose). In agreement, Kaye et al (2002), who published the international 
table of glycemic index and glycemic load values, found that the GI of honey (0.55 ± 0.05) 
was lower than that of sucrose (1.10 ± 0.21). Also, Shambaugh et al (1990) found that sucrose 
caused higher blood sugar readings than honey in normal volunteers. In the study of 
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Samnata et al (1985), honey ingestion in both diabetics (IDDM) and non-diabetics also 
resulted in a significantly lower PII compared to the glucose and sucrose. In the study done 
byAl-Waili (2004), honey compared with dextrose and sucrose caused a lower elevation of 
plasma glucose levels (PGL) in both diabetics (IDDM) and normal subjects. In an attempt to 
explain his results, he stated that the mild reduction of plasma glucose levels obtained by 
honey might be a result of the fructose content of honey which requires metabolic 
transformation in the liver, a slow process conferring relatively low-GI on these sugars 
(Jenkins et al., 1981; Wolever et al., 1991). Also, Watford (2002) demonstrated that very small 
amounts of fructose, which is the main component of honey, could increase hepatic glucose 
uptake and glycogen storage, as well as reduce peripheral glycemia which could be beneficial 
in diabetic patients. In the study performed by Agrawal et al (2007), honey was found to 
produce an attenuated postprandial glycemic response especially in subjects with glucose 
intolerance. They referred these results to the possibility that the glucose component of honey 
might be poorly absorbed from the gut epithelium. Also, Tirgoviste et al (1983) studied blood 
glucose and plasma insulin responses to various carbohydrates in type 2 diabetes, and they 
found that the increase in plasma glucose was significantly higher after administration of more 
refined carbohydrates such as glucose than after the complex ones such as honey. Meanwhile, 
Oizumi et al (2007) and Arai et al (2004) found that consumption of a palatinose (a 
disaccharide found in honey)-based balanced formula suppressed postprandial 
hyperglycemia, glycemic and peak incremental indices and produced beneficial effects on the 
metabolic syndrome–related parameters (namely, the lipid profile and visceral fat 
accumulation) in diabetic patients. They stated the reason of this observation to be due to the 
fact that although palatinose is completely absorbed, yet it has the specific characteristics of 
delayed digestion and absorption as reported by Dahlquist et al (1963) and Lina et al (2002).  
Our results showed that honey, compared to glucose and sucrose, caused a significant 
elevation in the C-peptide levels in non-diabetic subjects. Meanwhile, in diabetic patients, the 
plasma C-peptide levels did not differ significantly between the three types of sugars. To our 
knowledge, no similar work was done to study the effects of honey on C-peptide levels in type 
1 diabetes mellitus. However, several studies were performed in healthy and in type 2 diabetic 
patients to evaluate the effects of honey on the insulin and C-peptide levels, and the results 
were controversial. In the study of Al Waili (2003), inhalation of honey solution, when 
compared with hyperosmolar dextrose and hypoosmolar distilled water, resulted in a 
significant elevation of plasma insulin and C-peptide in both normal individuals and in 
patients with type 2 diabetes mellitus. However, in 2004, the same author found that honey 
ingestion, when compared with sucrose, caused a greater elevation of insulin and C-peptide in 
type 2 diabetic patients, while in healthy subjects dextrose ingestion caused a significant 
elevation of plasma insulin and C-peptide when compared with honey. The author 
hypothesized that honey may have the ability to stimulate insulin production and secretion 
from the pancreas than do sucrose in type 2 diabetes mellitus. On the other hand, Bornet et al 
(1985) reported no significant changes in plasma insulin levels after honey ingestion compared 
to sucrose in type 2 diabetics. Liljeberg et al (1999) found that high-GI foods induced a greater 
elevation of blood insulin than did low glycemic index meals (like honey). Elliott et al (2002) 
tried to explore whether fructose consumption might be a contributing factor to the 
development of obesity and the accompanying metabolic abnormalities observed in the insulin 
resistance syndrome and they found that honey intake caused a significant lowering of plasma 
insulin and C-peptide in normal subjects when compared to sucrose and dextrose. They 
related their findings to the fructose content of honey which does not stimulate insulin 
secretion from pancreatic beta cells and that consumption of foods and beverages containing 
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fructose produced a smaller postprandial insulin excursions than did consumption of glucose-
containing carbohydrates (Glinsmann & Bowman, 1993). Also, Watford et al (2002) stated that 
very small amounts of fructose, which is the main component of honey, could increase hepatic 
glucose uptake and glycogen storage, as well as reduce peripheral glycemia and thus insulin 
levels. Ionescu-Tirgoviste et al (1983) studied the blood glucose and plasma insulin responses 
to some simple carbohydrates (glucose, fructose, lactose) and some complex ones (apples, 
potatoes, bread, rice, carrots and honey) in 32 type 2 (non-insulin-dependent) diabetic patients, 
and they found that increases in plasma insulin were significantly higher after the more 
refined carbohydrates (glucose, fructose and lactose) than after the more complex ones (apples, 
potatoes, rice, carrots and honey, P less than 0.01).  
We hypothesize that honey might have a direct stimulatory effect on the healthy beta cells of 
pancreas; an effect which may be related to the non-sugar part of honey. This hypothesis is 
based on the finding that honey caused significant postprandial increase in the C-peptide 
level despite its lower glycemic and peak incremental indices when compared to either 
glucose or sucrose. On the other hand, the lack of significant increase in C-peptide levels 
among diabetic patients might be due to the minimal residual function of the patient’s 
pancreatic beta cells, which is beyond their capacity of further postprandial response. This 
proposal is backed up by the findings of Pozzan et al (1997) who investigated the relation 
between the fasting C-peptide level and the ability to respond to a particular stimulus, and 
they reported that there is a positive significant correlation between the basal value (BV) and 
the peak value (PV) of C-peptide in insulin dependent diabetic patients and that positive 
responses need a minimal basal level of 0.74 ng/ml. In all our studied patients, the basal C-
peptide level was less than 0.7 ng/ml. Also other authors found significant correlations 
between the basal and the maximum C-peptide values after a stimulus. However, they 
reported different basal values which can respond to stimulation. Such values were 0.09 
(Clarson et al., 1987), 0.18 (Eff et al., 1989) and 0.39 ng/ml (Faber & Binder, 1977). The 
variation in these levels was probably due to the different ages and different diabetes 
duration of the studied populations (Pozzan et al., 1997).  
6. Conclusions and recommendations  
1. Honey has a lower glycemic and peak incremental indices compared to glucose and 
sucrose in both type 1 diabetic patients and non-diabetics. Therefore, we recommend 
using honey as a sugar substitute in type 1 diabetic patients.  
2. In spite of its significantly lower glycemic and peak incremental indices, honey caused 
significant post- prandial rise of plasma C-peptide levels when compared to glucose 
and sucrose in non-diabetics; indicating that honey may have a direct stimulatory effect 
on the healthy beta cells of pancreas. On the other hand, C-peptide levels were not 
significantly elevated after honey ingestion when compared with either glucose or 
sucrose in type 1 diabetic patients. Whether or not ingestion of honey in larger doses 
or/and for an extended period of time would have a significant positive effect on the 
diseased beta cells, needs further studies. 
7. References   
Agrawal, O.; Pachauri, A.; Yadav, H.; Urmila, J.; Goswamy, H.; Chapperwal, A.; Bisen, P. & 
Prasad, G. (2007). Subjects with impaired glucose tolerance exhibit a high degree of 
tolerance to honey. J Med Food 10(3):473–478 
www.intechopen.com
 
Type 1 Diabetes – Complications, Pathogenesis, and Alternative Treatments 
 
434 
Al Waili, N. (2004). Natural honey lowers plasma glucose, C-reactive protein, homocysteine, 
and blood lipids in healthy, diabetic, and hyperlipidemic subjects: comparison with 
dextrose and sucrose. J Med Food 7(1):100–107 
Al Waili, N. & Boni, N. (2003). Natural honey lowers plasma prostaglandin concentrations 
in normal individuals. J Med Food 6(2):129–133 
Al-Waili, N. (2003). Intrapulmonary administrations of natural honey solution, 
hyperosmolar dextrose or hyperosmolar distill water to normal individuals and to 
patients with type 2 diabetes mellitus or hypertension: their effects on blood 
glucose level, plasma insulin and C-peptide, blood pressure and peak expiratory 
flow rate. Eur J Med Res 8(7):295–303 
American Diabetes Association. (2001). Report of the expert committee on the diagnosis and 
classification of diabetes mellitus (committee report).Diabetes care 24, (Suppl.1) 
American Diabetes Association (2002). Evidence-based nutrition principles and 
recommendations for the treatment and prevention of diabetes and related 
complications. Diabetes Care 25:202–212  
Arai, H.; Mizuno, A.; Matsuo, K.; Fukaya, M.; Sasaki, H.; Arima, H.; Matsuura, M.; Taketani, 
Y.; Doi, T. & Takeda, E. (2004). Effect of a novel palatinose-based liquid balanced 
formula (MHN-01) on glucose and lipid metabolism in male Sprague-Dawley rats 
after short- and long-term ingestion. Metabolism 53:977–983 
Bogdanov, S. (December 2010).  Book of Honey, Chapter 5, Honey Composition, Bee 
Product Science, available from www.bee-hexagon.net 
Bornet, F.; Haardt, M.; Costagliola, D.; Blayo, A. & Slama, G. (1985). Sucrose or honey at 
breakfast has no additional acute hyper-glycemic effect over an isoglucidic amount 
of bread in type 2 diabetic patients. Diabetologia 28(4):213–217 
Brand, J.; Nicholson, P.; Thorburn, A. & Truswell, A. (1985). Food processing and the 
glycemic index. Am J Clin Nutr. Dec; 42(6):1192-6 
Bretzel, R.; Voigt, K. & Schatz, H. (1998). The United Kingdom Prospective Diabetes Study 
(UKPDS) implications for the pharmacotherapy of type 2 diabetes mellitus. Exp 
Clin Endocrinol diabetes 106: 369-372 
Chiasson, J.; Josse, R.; Gomis, R.; Hanefeld, M.; Karasik, A. & Laakso, M. (2002). STOP- 
NIDDM Trial Research Group. Acarbose for prevention of type 2 diabetes mellitus: 
the STOP- NIDDM trial. Lancet 259: 2072-2077 
Clarson, C.; Daneman, D.; Drash, A.; Beckert, D. & Ehelich, R. (1987). Residual B-cell 
function in children with IDDM; reproducibility of testing and factors influencing 
insulin secretory reserve. Diabetes Care 10(1):33–38 515 
Connors, T. ( September 2000). Interpreting your C-peptide values; diabetes health, available 
from http://www.diabeteshealth.com.html. Updated 2000/09, accessed Jan 2008 
Dahlquist, A.; Auricchio, S.; Semenza, G. & Prader, A. (1963). Human intestinal 
disaccharidases and hereditary disaccharide intolerance: the hydrolysis of sucrose, 
isomaltose, palatinose (isomaltulose), and 1, 6-a-oligosaccharide (isomalto-
oligosaccharide) preparation. J Clin Invest 42:556–562 
Daniel, W. (1995). Biostatistics: a foundation for analysis in the health sciences, 6th edn. 
Wiley, New York 
Eff, C.; Fabet, O. & Deckert, T. (1989). Persistent insulin secretion assessed by plasma C-
peptide estimation in long-term juvenile diabetes with a low insulin requirement. 
Diabetologia 32:305– 311 
Elliott, S.; Keim, N. & Stern, J. (2002).  Fructose, weight gain and the insulin. Am J Clin Nutr 
76:911–922 
www.intechopen.com
 
Honey and Type 1 Diabetes Mellitus 
 
435 
Faber, O. & Binder, C. (1977). B-cell function and blood glucose control in insulin dependent 
diabetes within the first month of insulin treatment. Diabetologia 13:263–268 
FAO/WHO. (1998). Carbohydrates in human nutrition (Paper No. 66). Food and 
Agricultural Organization and Geneva, World Health Organization, Rome 
Frankel, S.; Robinson, G. & Berenbaum, M. (1998). Antioxidant capacity and correlated 
characteristics of 14 unifloral honeys. J Apic Res 37(1):27–31 
Gannon, M.; Nuttall, F.; Westphal, S.; Neil, B. & Seaquist, E. (1989). Effects of dose of 
ingested glucose on plasma metabolite and hormone responses in type II diabetic 
subjects.  Diabetes Care12:544-552 
Gheldof, N. & Engeseth, N. (2002). Antioxidant capacity of honeys from various floral 
sources based on the determination of oxygen radical absorbance capacity and 
inhibition of in vitro lipoprotein oxidation in human serum samples. J Agric Food 
Chem 50(10):3050–3055 
Glinsmann, W. & Bowman, B. (1993). The public health significance of crystalline fructose, 
glucose tolerance. Am J Clin Nutr 77(3):612–621 506 
Gross, H.; Polagruto, J.; Zhu, Q.; Kim, S.; Schramm, D. & Keen, C. (2004). Effect of honey 
consumption on plasma antioxidant status in human subjects. Abstracts of Papers 
of the American Chemical Society, 227: U29 
Hanefeld, M.; Cagatay, M.; Petrowitsch, T.; Neuser, D.; Petzinna, D. & Rupp, M. (2004). 
Acarbose reduces the risk of myocardial infarction in type 2 diabetic patients: meta-
analysis of seven long- term studies. Eur Heart J 25:10-16 
Ido, Y.; Vindigni, A. & Chang, K. (1997). Prevention of vascular and neural dysfunction in 
diabetic rats by C-peptide. Science 277(5325):563–566 
Ionescu-Tirgoviste, C.; Popa, E.; Sintu, E.; Mihalache, N.; Cheta, D. & Mincu, I. (1983). Blood 
glucose and plasma insulin responses to various carbohydrates in type 2 non-
insulin-dependent diabetes. Diabetologia 24:80–84 
Jenkins, D. (1987). The glycemic index and the dietary treatment of hypertriglyceridemia 
and diabetes. J Am Coll Nutr 61:11–17 
Jenkins, D.; Wolever, T.; Taylor, R.; Barker, H.; Fielden, H.; Baldwin, J.; et al (1981). Glycemic 
index of foods: a physiological basis for carbohydrate exchange. Am J Clin Nutr 
34(3):362– 366 
Jennie, B.; Hayne, S.; Petocz, P. & Stephen, C. (2003). Low-glycemic index diets in the 
management of diabetes. Diabetes Care 26:2261–2267 
Kaye, F.; Holt, S. & Janette, C. (2002).  International table of glycemic index and glycemic 
load values. Am J Clin Nutr 76:5n56 
Laakso, M. & Lehto, S. (1997). Epidemiology of macrovascular disease in diabetes. J Diabetes 
Rev 5: 294-315 
Liljeberg, H.; Akerberg, A. & Bjorck, I. (1999). Effect of the glycemic index and content of 
indigestible carbohydrates of cereal-based breakfast meals on glucose tolerance at 
lunch in healthy subjects. Am J Clin Nutr 69:647–655 503 
Lina, B.; Jonker, D. & Kozianowski, G. (2002). Isomaltulose (palatinose): a review of 
biological and toxicological studies. Food Chem Toxicol 40:1375–1381 
Molan, P. (1992). The antibacterial activity of honey. 1. The nature of the antibacterial 
activity. Bee World 73(1):5–28 (2. Variation in the potency of the antibacterial 
activity. Bee World 73(2): 59–76) 
Molan, P. (1997). Honey as an antimicrobial agent. In: Mizrahi A, Lensky Y (eds) Bee 
products: properties, applications and api-therapy. Plenum, London, pp 27–37 
www.intechopen.com
 
Type 1 Diabetes – Complications, Pathogenesis, and Alternative Treatments 
 
436 
Nakagami, T. & the DECODA  Study Group. (2004). Hyperglycemia and mortality from all 
causes and from cardiovascular disease in five populations of Asian origin. 
Diabetologia 47: 385-394 
Oizumi, T.; Daimon, M.; Jimbu, Y.; Kameda, W.; Arawaka, N.; Yamaguchi, H.; Ohnuma, H.; 
Sasaki, H. & Kato, T. (2007). A palatinose- based formula improves glucose 
tolerance, serum free fatty acid levels and body fat composition. Tohoku J Exp Med 
212:91–99 
Ostman, E.; Liljeberg, H.; Elmstahl, H. & Bjorck, I. (2001). Inconsistency between glycemic 
and insulinemic responses to regular and fermented milk products. Am J Clin Nutr 
74(1):96–100 
Peters, A. & Schriger, D. (1997). Impact of new diagnostic criteria on the diagnosis of 
diabetes (abstract). Diabetes 46 (Suppl.1):7A 
Pozzan, R.; Dimetz, T.; Gazolla, H. & Gomes, M. (1997). Discriminative capacity of fasting C-
peptide levels in a functional test according to different criteria of responser to a 
stimulus; a study of Brazilian insulin-dependent diabetic patients. Braz J Med Biol 
Res 30(10):1169–1174 511 
Risso, A.; Mercuri, F.; Quagliaro, L.; Damante, G. & Ceriello, A. (2001). Intermittent high 
glucose enhances apoptosis in human umbilical vein endothelial cells in culture. 
Am J Physiol Endocrinol Metab 281: E924-E930 
Samanta, A.; Burden, A. & Jones, G. (1985). Plasma glucose responses to glucose, sucrose, 
and honey in patients with diabetes mellitus: an analysis of glycemic and peak 
incremental indices. Diabet Med 2:371–373 
Shambaugh, P.; Worthington, V. & Herbert, J. (1990). Differential effects of honey, sucrose, 
and fructose on blood sugar levels. J Manip Physiol Ther 13:322–325 
Steinberg, D.; Kaine, G. & Gedalia, I. (1996). Antibacterial effect of propolis and honey on 
oral bacteria. Am J Dent 9(6):236–239 
Theunissen, F.; Grobler, S. & Gedalia, I. (2001). The antifungal action of three South African 
honeys on Candida albicans. Apidologie 32(4):371–379 
Tominaga, M.; Eguchi, H.; Manaka, H.; Igarashi, K.; Kato, T. & Sekikawa, A. (1999). 
Impaired glucose tolerance is a risk factor for cardiovascular disease, but not 
impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care 22: 920-924 
Watford, M. (2002).  Small amounts of dietary fructose dramatically increase hepatic glucose 
uptake. Nutr Rev 60(8):253–257 
White, JW Jr. (1980). Detection of honey adulteration by carbohydrate analysis. JAOAC 
63(1):11–18 
White, JW Jr.; et al. (1962). Composition of American honeys. Tech. Bull. 1261. Agricultural 
Research Service, USDA, Washington DC 
White, J. (1975). Composition of honey. In Crane, E (ed.) Honey. A Comprehensive survey, 
Heinemann Edition; London, pp 157-206 
William, C. & Ruchi, M. (2005). Glucose tolerance test, available from  
 http://www.medicinenet.com/glucose_tolerance_test/article.htm. 
2005.medicinenet 
Wolever, T.; Jenkins, D.; Jenkins, A. & Josse, R. (1991). The glycemic index: methodology and 
clinical implications. Am J Clin Nutr 54(5):846–854 
www.intechopen.com
Type 1 Diabetes - Complications, Pathogenesis, and Alternative
Treatments
Edited by Prof. Chih-Pin Liu
ISBN 978-953-307-756-7
Hard cover, 470 pages
Publisher InTech
Published online 21, November, 2011
Published in print edition November, 2011
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
This book is intended as an overview of recent progress in type 1 diabetes research worldwide, with a focus on
different research areas relevant to this disease. These include: diabetes mellitus and complications,
psychological aspects of diabetes, perspectives of diabetes pathogenesis, identification and monitoring of
diabetes mellitus, and alternative treatments for diabetes. In preparing this book, leading investigators from
several countries in these five different categories were invited to contribute a chapter to this book. We have
striven for a coherent presentation of concepts based on experiments and observation from the authors own
research and from existing published reports. Therefore, the materials presented in this book are expected to
be up to date in each research area. While there is no doubt that this book may have omitted some important
findings in diabetes field, we hope the information included in this book will be useful for both basic science
and clinical investigators. We also hope that diabetes patients and their family will benefit from reading the
chapters in this book.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Mamdouh Abdulrhman, Mohamed El Hefnawy, Rasha Ali and Ahmad Abou El-Goud (2011). Honey and Type
1 Diabetes Mellitus, Type 1 Diabetes - Complications, Pathogenesis, and Alternative Treatments, Prof. Chih-
Pin Liu (Ed.), ISBN: 978-953-307-756-7, InTech, Available from: http://www.intechopen.com/books/type-1-
diabetes-complications-pathogenesis-and-alternative-treatments/honey-and-type-1-diabetes-mellitus
© 2011 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
